This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B21.8 | Special Copayment Reduction: V103 (severe intractable disease, 5 years) |
| B. Synonyms | HIV disease resulting in other malignant neoplasms; AIDS-related malignancy NOS |
| C. Adult onset | Likelihood of onset in adulthood: Very high — HIV-associated malignant neoplasms occur mainly in adults, and accumulated immunosuppression and exposure to oncogenic viruses lead to carcinogenesis in adulthood. |
| 1-12. Main text | B21.8 is HIV disease resulting in other malignant neoplasms (non-AIDS-defining malignancies) not included in B21.0-B21.7, and includes lung cancer, hepatocellular carcinoma, anal cancer, cervical cancer, and head and neck squamous cell carcinoma. The occurrence of these non-AIDS-defining malignancies in persons with HIV has relatively increased since ART. Anal cancer is associated with HPV 16/18 infection and low anal CD4, and the risk in HIV-infected MSM is 19 times or more that of the general population. For hepatocellular carcinoma, the risk increases 5- to 7-fold in patients with HIV co-infected with HBV or HCV. For lung cancer, smoking is the largest independent risk factor, but chronic HIV inflammation also contributes. Standard treatment for each malignant neoplasm is applied together with ART. For prevention, HPV vaccine, HBV/HCV treatment, smoking cessation, and regular cancer screening are recommended. |
| 13. References | Includes 10 recent references |
The occurrence of malignant neoplasms in persons with HIV has been studied continuously since the first report of AIDS in 1981. AIDS-defining malignancies (KS, Burkitt lymphoma, invasive cervical cancer) were recognized first, and their incidence has decreased greatly since ART. B21.8 includes the other malignant neoplasms.
As the life expectancy of persons with HIV has been greatly extended since the introduction of ART, the relative importance of non-AIDS-defining malignancies has increased. Large cohort studies since the 2000s have reported that the risk of lung cancer, liver cancer, anal cancer, head and neck cancer, and others in persons with HIV is markedly higher than in the general population. These non-AIDS-defining malignancies now account for a major share of HIV-related cancer deaths.
In the 2010s, integrated cancer care guidelines for persons with HIV began to be developed. The HIV Medicine Association (HIVMA), the Infectious Diseases Society of America (IDSA), the WHO, and others published expert guidelines on cancer screening, prevention, and treatment in persons with HIV. In particular, HPV-related screening protocols for anal cancer and cervical cancer were strengthened.
B21.8 is HIV disease resulting in other malignant neoplasms (non-AIDS-defining malignancies) not included in B21.0-B21.7, and includes lung cancer, hepatocellular carcinoma, anal cancer, cervical cancer, and head and neck squamous cell carcinoma. The occurrence of these non-AIDS-defining malignancies in persons with HIV has relatively increased since ART. Anal cancer is associated with HPV 16/18 infection and low anal CD4, and the risk in HIV-infected MSM is 19 times or more that of the general population. For hepatocellular carcinoma, the risk increases 5- to 7-fold in patients with HIV co-infected with HBV or HCV. For lung cancer, smoking is the largest independent risk factor, but chronic HIV inflammation also contributes. Standard treatment for each malignant neoplasm is applied together with ART. For prevention, HPV vaccine, HBV/HCV treatment, smoking cessation, and regular cancer screening are recommended.
HIV-induced immunosuppression impairs tumor surveillance and permits proliferation of malignant cells. Oxidative stress and inflammation from chronic immune activation cause DNA damage and raise the risk of carcinogenesis. Co-infection with oncogenic viruses (HPV, HBV, HCV, HHV-8, EBV) contributes directly to the development of specific malignant neoplasms.
Not a hereditary disease. In HIV-associated malignant neoplasms, host gene polymorphisms (CCR5 Δ32, HLA type, innate immunity-related genes) affect the rate of HIV progression and thereby indirectly contribute to the risk of malignant neoplasms. Each type of malignant neoplasm has its own specific somatic mutation pattern, and some accumulate faster in the inflammatory and immune-activated environment associated with HIV.
In HPV-associated malignant neoplasms (anal cancer, cervical cancer, oropharyngeal cancer), degradation of p53 and suppression of pRb function by the HPV E6 and E7 proteins is the core carcinogenic mechanism. HIV infection accelerates the progression of HPV-related cellular lesions, promoting the transition from precancerous lesions to invasive cancer. In hepatocellular carcinoma, hepatocyte genomic instability due to HBV/HCV integration or chronic inflammation is the main pathway of carcinogenesis.
The standardized incidence ratios of non-AIDS-defining malignancies in persons with HIV are reported as 19 for anal cancer, 11 for Hodgkin lymphoma, 5-7 for liver cancer, 2-3 for lung cancer (including the contribution of smoking), and 2-3 for oropharyngeal cancer. Studies show that in the ART era, about 30-40% of AIDS-related cancer deaths are attributable to non-AIDS-defining malignancies. In Korea as well, cases of hepatocellular carcinoma (co-infected with chronic hepatitis B), anal cancer, lung cancer, and others are increasing in persons with HIV.
HIV-induced immunosuppression reduces CTL- and NK cell-mediated killing of tumor cells and permits growth of tumor clones. Sustained activation of the NF-κB and STAT3 pathways due to chronic HIV infection promotes tumor cell proliferation and resistance to apoptosis. Bacterial translocation due to collapse of intestinal mucosal immunity raises systemic LPS levels, worsens chronic inflammation, and creates a carcinogenesis-promoting environment in multiple organs. The HIV Tat protein increases expression of angiogenesis-related growth factors (VEGF, FGF), providing a vascular environment favorable to tumor growth.
Symptoms specific to each type of malignant neoplasm appear. Anal cancer: anal pain, bloody stool, perianal mass, rectal bleeding. Lung cancer: cough (including bloody sputum), dyspnea, chest pain, hoarseness. Hepatocellular carcinoma: right upper quadrant pain, jaundice, ascites, weight loss. Oropharyngeal cancer: sore throat, dysphagia, cervical lymphadenopathy, oral ulcers. Systemic symptoms of weight loss, fever, fatigue, and anorexia commonly accompany them. Underlying HIV symptoms and malignant neoplasm symptoms overlap, so the clinical picture can be complex.
Physical findings appear according to the type of malignant neoplasm. Anal cancer: ulcerative or nodular lesions on anoscopy and proctoscopy. Lung cancer: abnormal chest auscultation, superior vena cava syndrome (upper-limb edema, facial flushing). Hepatocellular carcinoma: hepatomegaly, ascites, jaundice, spider angioma. Tumor markers: AFP (hepatocellular carcinoma), CEA (colorectal cancer), SCC (anal and cervical cancer), CA19-9 (cholangiocarcinoma). Cytopenia (with bone marrow involvement), liver function abnormalities, and elevated serum creatinine (renal involvement) may accompany.
Screening protocol for non-AIDS-defining malignancies in persons with HIV. Anal cancer: annual anal cytology in all HIV-infected MSM. HPV genotyping. High-resolution anoscopy if high-grade dysplasia is identified. Lung cancer: annual low-dose CT in HIV-infected persons aged 55 or older with a smoking history of 30 pack-years or more. Hepatocellular carcinoma: AFP + liver ultrasound at 6-month intervals in patients with HIV co-infected with HBV/HCV. Cervical cancer: annual Pap smear + HPV test. Oropharyngeal cancer: annual oral examination. Colorectal cancer: colonoscopy at 10-year intervals from age 50 (or 45).
The standard diagnostic tests for each malignant neoplasm are performed. Anal cancer: biopsy under anoscopy, pretreatment MRI (extent of rectal involvement), PET-CT staging. Lung cancer: bronchoscopic or CT-guided biopsy, PET-CT, molecular biomarkers (EGFR, ALK, ROS1, PD-L1). Hepatocellular carcinoma: noninvasive diagnosis is possible by the characteristic vascular pattern (arterial enhancement + washout) on dynamic CT/MRI; biopsy if uncertain. Oropharyngeal cancer: endoscopic biopsy, HPV p16 immunohistochemistry, CT/MRI evaluation of the neck and chest.
Standard treatment for each malignant neoplasm is applied while maintaining ART. Anal cancer: concurrent radiation therapy with mitomycin C + 5-fluorouracil (standard). Lung cancer: surgery, radiation, chemotherapy, EGFR/ALK targeted therapy, and immune checkpoint inhibitors (PD-1/PD-L1; toxicity profile must be monitored in patients with HIV) according to stage and molecular markers. Hepatocellular carcinoma: sorafenib/lenvatinib (advanced), TACE (intermediate stage), resection and radiofrequency ablation (early stage). In all treatments, monitor drug interactions with ART, hepatotoxicity, and bone marrow toxicity.
The prognosis of non-AIDS-defining malignancies depends more on tumor type and stage than that of AIDS-defining malignancies. When detected early (by screening), a prognosis similar to that of the general population can be expected. In advanced stages, treatment toxicity is higher and the complete remission rate is lower because of HIV immunosuppression. Persons with HIV whose immunity has recovered with ART have a better cancer treatment prognosis than those whose immunity has not. Early diagnosis, aggressive treatment, and an excellent ART response are the three pillars of improved prognosis.
Maintaining CD4 through ART is the basic prevention that preserves tumor surveillance. HPV vaccine (Gardasil 9): prevents anal cancer, cervical cancer, and oropharyngeal cancer. Recommended for all persons with HIV (standard for age 26 or younger; shared decision-making for ages 27-45). HBV vaccine (for the uninfected). HCV treatment (DAA regimen): prevents hepatocellular carcinoma. Smoking cessation: prevents lung cancer and head and neck cancer. Adhere to regular cancer screening protocols. Early diagnosis of HIV and early initiation of ART are most important for reducing overall cancer risk.
Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America. Ann Intern Med. 2015;163(7):507-518. DOI: 10.7326/M14-2768. PMID: 26167721.
Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study. J Natl Cancer Inst. 2005;97(6):425-432. DOI: 10.1093/jnci/dji072. PMID: 15770005.
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS. Lancet. 2007;370(9581):59-67. DOI: 10.1016/S0140-6736(07)61050-2. PMID: 17617273.
Park LS, Tate JP, Sigel K, et al. Association of viral suppression with lower AIDS-defining and non-AIDS-defining cancer incidence. Ann Intern Med. 2018;169(2):87-96. DOI: 10.7326/M17-2927. PMID: 29946680.
Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123(1):187-194. DOI: 10.1002/ijc.23487. PMID: 18435450.
Brickman C, Palefsky JM. Cancer in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era. Curr HIV/AIDS Rep. 2015;12(4):388-396. DOI: 10.1007/s11904-015-0283-3. PMID: 26330076.
Mitsuyasu RT. Non-AIDS-defining malignancies in HIV. Top HIV Med. 2008;16(4):117-121. PMID: 18957700.
WHO. Guidelines on HIV-related cancer prevention, treatment and surveillance. WHO. 2022. ISBN: 9789240046085.
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525-1533. DOI: 10.1016/S0140-6736(13)61809-7. PMID: 24152939.
Korea Disease Control and Prevention Agency (KDCA). 2023 HIV/AIDS Notification Annual Report. Korea Disease Control and Prevention Agency. 2024. https://www.kdca.go.kr